Zimbabwe has declined a substantial American healthcare agreement worth $367m (£272m) spanning five years because of the United States' insistence on sensitive data.
This rejection came to light following a official document from December was leaked, which showed President Emmerson Mnangagwa believed the arrangement was "skewed".
A government spokesman has since explained that the United States was seeking health data for scientific study and commercial gain while refused to guarantee the benefits from any future treatments.
"We are forced to start the difficult and regrettable task of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had donated over $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for continued talks to find a deal acceptable to all parties so the nation's vital HIV programme can be sustained.
Broader Context
Zimbabwe's decision follows a similar situation in Kenya, where a high court suspended a similar health funding agreement after legal challenges were raised about the security of citizens' health data.
After resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had overseen aid for the American government, but Trump claimed its spending was "inefficient" and his government was pursuing direct bilateral agreements to enhance transparency and responsibility.
Based on statements, 16 African countries have so far signed similar health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership would have delivered immense advantages for Zimbabwean communities, particularly the 1.2 million currently on antiretroviral therapy via US-supported programmes," Tremont said.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to provide its biological resources and data indefinitely, with no corresponding promise of benefiting from any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," he stated.
"Put simply, our nation would supply the raw materials for medical research with no certainty that the end products would be accessible to our people if a new disease outbreak arise."
National Interest and Global Health
Mangwana further pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were undermining frameworks previously set up through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme created to manage future global health emergencies.
"This system is designed to guarantee that when a country provides its samples, the benefits – including medicines and cures – are distributed fairly, not monopolised solely by those with the funds to create them."
The government's concerns over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We welcome ongoing discussions with our US partners on how future collaboration could be designed in a way that respects the sovereignty and interests of each country."
Health Experts Response
Medical experts said it recognised the government's concerns, but recommended that talks must proceed given that a large portion of the nation's Aids initiatives relied on foreign aid.
"In cases where technical issues arise, including those relating to information security or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," the group commented.
The situation underscores the complex tensions between receiving vital international aid and safeguarding a country's data in an ever more data-driven world.